Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA

Seems brilliant Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA something also

Missing values will not be replaced. The last observation carried forward will be determined for all parameters in noncompleted patients. Descriptive statistics will be used to characterize the patients at baseline. For the primary endpoint, a P-value P-values To our knowledge, the potential efficacy of metal trace elements against endometriosis-induced pelvic pain has never been Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA in a double-blind, randomized, placebo-controlled trial.

Therefore, this is the main originality of this pilot study. It was initially scheduled to identify Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA to recruit the patients on the sole basis of biopsy.

However, it appeared that it could seriously prolong the inclusion period needed to achieve the requested sample size because in practice, some centers do not perform a biopsy and because in case of relapse (frequent for endometriosis), most of the time, a biopsy is what happiness is performed at all. The diagnosis of endometriosis by visual inspection of the lesions will be based on the experience of the surgeon,23 and this is a key factor to obtain a high correlation between macroscopic visual diagnosis and pathological diagnosis of a biopsy specimen.

Therefore, this is a particular challenge of this study to be able to show a superiority of metal trace elements versus placebo in the context of an add-on therapy. Instead of measuring pelvic pain at specific, fixed, and limited time points, we have decided to record it every day during the placebo run-in period and the 120-day treatment phase and Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA compare the changes versus baseline in pain AUCs in the placebo and metal trace elements-treated groups.

Together Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA the analysis of the QoL by means of the EHP-30 questionnaire, it will allow coping skills to aggressive to a potential positive effect of metal trace elements versus placebo on the QoL in endometriosis patients, which is at the end of the day the best and most important clinical objective to achieve in order to decrease the burden of endometriosis.

There is an important limitation to the study in terms of mechanistic approach. While, we were asked by the company Pronutri to evaluate its product in a strict double-blind, randomized controlled study, as is the case for the majority of multicomponent drugs, plant extracts, food supplements, and homeopathic treatments, it will be impossible to know which trace element(s) is(are) responsible for an eventual positive effect in endometriosis-induced pelvic pain.

At the opposite, if we fail to achieve the primary endpoint of the study, it will never be possible to improve these products. Therefore, this is a kind of all or none approach, which is frustrating for scientists, but we have to live with it. Ultimately, it is the QoL of our patients that is important and not the mechanism of action of a drug, whatever it is. This study is entirely supported by Laboratoires Pronutri.

Didier Oberweis, Patrick Madelenat, and Michelle Nisolle are the principal investigators of this study. Their centers have received a financial support from Laboratoires Pronutri just for conducting this study. He contributed to the revision of the protocol and to the setup of the study.

The authors report no other conflicts of interest in this work. Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Peterson CM, Johnstone EB, Hammoud AO, quinacrine al; ENDO Study Working Group.

Risk netlook associated with endometriosis: importance of study population for characterizing disease in the ENDO study. Am J Obstet Gynecol. Donnez J, Chantraine Kalliga (Desogestrel And Ethinyl Estradiol Tablets)- FDA, Nisolle M. The efficacy of medical and surgical treatment of endometriosis-associated infertility: arguments in duloxetine of a medico-surgical aproach.

Heilier JF, Donnez J, Lison D. Organochlorines and endometriosis: a mini-review. Zeitschrift Umwelt Medizin Gesellschaft.

Fedele L, Bianchi S, Zanconato G, Berlanda N, Raffaelli R, Fontana E. Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery. Chapron C, Vercellini P, Barakat H, Vieira M, Dubuisson JB. Management of ovarian endometriomas. Jones KD, Sutton CJ. Laparoscopic management of ovarian endometriomas: a critical review of current practice.



06.09.2019 in 00:41 Tulkis:
I about it still heard nothing

06.09.2019 in 16:45 Nak:
I am final, I am sorry, but this variant does not approach me.

11.09.2019 in 16:40 Torr:
I think, that you are mistaken. I can prove it. Write to me in PM, we will talk.

13.09.2019 in 09:31 Kazigal:
In it something is. Many thanks for the information. It is very glad.

14.09.2019 in 22:26 Mikajas:
I consider, that you commit an error. Write to me in PM.